Intellia Therapeutics (NTLA) EBT Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported EBT Margin of 633.49% for Q1 2026, up 4134.0% year-over-year from 14.96% in Q1 2025, and down 58.09% on a QoQ basis from 400.72% in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of EBT Margin data on file, last reported at 633.49% in Q1 2026.
- Quarterly EBT Margin rose 4134.0% year-over-year to 633.49% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 597.53% (up 49376.0% YoY) and the FY2025 annual result came in at 608.53%, up 23197.0% from the prior year.
- EBT Margin fell to 633.49% in Q1 2026 per NTLA's latest filing, from 400.72% in the prior quarter.
- Across five years, EBT Margin topped out at 6647.52% in Q4 2023 and bottomed at 1820.05% in Q2 2024.
- The 5-year median for EBT Margin is 771.63% (2022), against an average of 431.25%.
- The widest annual swing landed in 2022, when EBT Margin surged 2310050 bps; it then plunged 762481 bps in 2024.
- Tracing NTLA's EBT Margin over 5 years: stood at 771.63% in 2022, then soared by 961 bps to 6647.52% in 2023, then slumped by 115 bps to 977.29% in 2024, then soared by 59 bps to 400.72% in 2025, then slumped by 58 bps to 633.49% in 2026.
- Per Business Quant, the three latest NTLA EBT Margin figures stand at 633.49% (Q1 2026), 400.72% (Q4 2025), and 760.14% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | -633.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -633.49% |
| Dec 31, 2025 | -400.72% |
| Sep 30, 2025 | -760.14% |
| Jun 30, 2025 | -720.21% |
| Mar 31, 2025 | -674.83% |
| Dec 31, 2024 | -977.29% |
| Sep 30, 2024 | -1,455.91% |
| Jun 30, 2024 | -1,820.05% |
| Mar 31, 2024 | -350.34% |
| Dec 31, 2023 | 6,647.52% |
| Sep 30, 2023 | -987.05% |
| Jun 30, 2023 | -880.40% |
| Mar 31, 2023 | -793.10% |
| Dec 31, 2022 | -771.63% |
| Sep 30, 2022 | -780.83% |
| Jun 30, 2022 | -695.64% |
| Mar 31, 2022 | -1,277.16% |
| Dec 31, 2021 | -621.69% |
| Sep 30, 2021 | -23,881.33% |
| Jun 30, 2021 | -1,050.47% |
| Mar 31, 2021 | -716.91% |
| Dec 31, 2020 | -639.76% |
| Sep 30, 2020 | -125.29% |
| Jun 30, 2020 | -199.18% |
| Mar 31, 2020 | -636.12% |
| Dec 31, 2019 | -258.56% |
| Sep 30, 2019 | -222.63% |
| Jun 30, 2019 | -231.00% |
| Mar 31, 2019 | -210.29% |
| Dec 31, 2018 | -241.95% |
| Sep 30, 2018 | -306.45% |
| Jun 30, 2018 | -289.42% |
| Mar 31, 2018 | -285.93% |
| Dec 31, 2017 | -359.37% |
| Sep 30, 2017 | -209.87% |
| Jun 30, 2017 | -263.53% |
| Mar 31, 2017 | -203.23% |
| Dec 31, 2016 | -187.72% |
| Sep 30, 2016 | -153.67% |
| Jun 30, 2016 | -164.05% |
| Mar 31, 2016 | -376.42% |
| Dec 31, 2015 | -324.34% |
| Sep 30, 2015 | -195.56% |
| Jun 30, 2015 | -248.51% |
| Mar 31, 2015 | -92.92% |